doi toshihiko 土井俊彦

… Alternative Names

Doi Toshihiko 土井俊彦

Less

Researcher Number	20522907
Other IDs
Affiliation (Current)	2025: 国立研究開発法人国立がん研究センター, 東病院, 病院長
Affiliation (based on the past Project Information) *help	2017 – 2021: 国立研究開発法人国立がん研究センター, 東病院, 科長 2016: 国立がん研究センター先端医療開発センター免疫TR分野, 先端医療科長
Review Section/Research Field	Except Principal Investigator Tumor biology / Tumor therapeutics / General surgery / Gastroenterology
Keywords	Except Principal Investigator 免疫学 / がん免疫 / CD8陽性T細胞 / 癌 / 腫瘍浸潤リンパ球 / がん免疫療法 / 腫瘍免疫 / 免疫制御 / 腫瘍微小環境 / 発がん … More / 免疫チェックポイント分子 / CD4陽性制御性T細胞 / 免疫抑制 / 免疫機能解析 / 遺伝子発現 / トリプルネガティブ乳癌 / pCR / predictor / TILs / 免疫染色 / TNBC / 亜分類 / TIL / トリプルネガティブ乳がん / ヒト研究 / トランスレーショナルリサーチ / Human Immunology / Human immunology / 制御性T細胞 Less

New Classification of triple negative breast cancer (TNBC) based on immune status with clinical characteristic
- Principal Investigator
  
  Kogawa Takahiro
- Project Period (FY)
  2017 – 2021
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  General surgery
- Research Institution
  National Cancer Center Japan
Immunosuppressive mechanisms for anti-tumor immune responses depending on antigenicity
- Principal Investigator
  
  西川博嘉
- Project Period (FY)
  2017
- Research Category
  
  Grant-in-Aid for Scientific Research (A)
- Research Field
  
  Tumor therapeutics
- Research Institution
  Nagoya University
Association of immune responses with racial differences of cancer development
- Principal Investigator
  
  Nishikawa Hiroyoshi
- Project Period (FY)
  2017 – 2021
- Research Category
  
  Grant-in-Aid for Scientific Research (S)
- Research Field
  
  Tumor biology
- Research Institution
  Nagoya University
Identification of new molecule for regulatory T cells in an anti-tumor immunity
- Principal Investigator
  
  Sugiyama Daisuke
- Project Period (FY)
  2015 – 2016
- Research Category
  
  Grant-in-Aid for Research Activity Start-up
- Research Field
  
  Gastroenterology
- Research Institution
  Nagoya University
  National Cancer Center Japan

All 2022 2021 2020 2019 2018

All Journal Article Presentation

[Journal Article] Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments2022
- Author(s)
  Kumagai S, Koyama S, Itahashi K, Tanegashima T, Lin YT, Togashi Y, Kamada T, Irie T, Okumura G, Kono H, Ito D, Fujii R, Watanabe S, Sai A, Aokage K, Suzuki J, Ishii G, Kuwata T, Sakamoto N, Kawazu M, Ueno T, Mori T, Yamazaki N, Tsuboi M, Yatabe Y, Kinoshita T, Doi T, Shitara K, Mano H, Nishikawa H
- Journal Title
  
  Cancer Cell
  
  Volume: 40 Issue: 2 Pages: 201-218
- DOI
  10.1016/j.ccell.2022.01.001
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-17H06162, KAKENHI-PROJECT-20H03461, KAKENHI-PROJECT-20H03694, KAKENHI-PROJECT-20H04519, KAKENHI-PROJECT-21H02772, KAKENHI-PROJECT-20K07383, KAKENHI-PROJECT-20K08531, KAKENHI-PROJECT-21K07112, KAKENHI-PROJECT-21K07252, KAKENHI-PROJECT-21K12117, KAKENHI-PROJECT-16H06279, KAKENHI-PROJECT-22KJ3156, KAKENHI-PROJECT-22H00455
[Journal Article] Potentiality of multiple modalities for single-cell analyses to evaluate the tumor microenvironment in clinical specimens2021
- Author(s)
  Kashima Yukie、Togashi Yosuke、Fukuoka Shota、et al.
- Journal Title
  
  Scientific Reports
  
  Volume: 11 Issue: 1 Pages: 341-341
- DOI
  10.1038/s41598-020-79385-w
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-20H03694, KAKENHI-PROJECT-19K22574, KAKENHI-PROJECT-17H06162
[Journal Article] Depletion of central memory CD8+ T cells might impede the antitumor therapeutic effect of Mogamulizumab2021
- Author(s)
  Maeda Yuka、Wada Hisashi、Sugiyama Daisuke、Saito Takuro、Irie Takuma、Itahashi Kota、Minoura Kodai、Suzuki Susumu、Kojima Takashi、Kakimi Kazuhiro、Nakajima Jun、Funakoshi Takeru、Iida Shinsuke、Oka Mikio、Shimamura Teppei、Doi Toshihiko、Doki Yuichiro、Nakayama Eiichi、Ueda Ryuzo、Nishikawa Hiroyoshi
- Journal Title
  
  Nature Communications
  
  Volume: 12(1) Issue: 1 Pages: 7280-7280
- DOI
  10.1038/s41467-021-27574-0
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PUBLICLY-20H04841, KAKENHI-PROJECT-17H06162, KAKENHI-PROJECT-19H03729, KAKENHI-PROJECT-20H04281, KAKENHI-PROJECT-21K07112, KAKENHI-PROJECT-20K21832
[Journal Article] The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies2020
- Author(s)
  Kumagai S,Togashi Y,Kamada T,Sugiyama E,Nishinakamura H,Takeuchi Y,Vitaly K,Itahashi K,Maeda Y,Matsui S,Shibahara T,Yamashita Y,Irie T,Tsuge A,Fukuoka S,Kawazoe A,Udagawa H,Kirita K,Aokage K,Ishii G,Kuwata T,Nakama K,Kawazu M,Ueno T,Yamazaki N,Goto K,Tsuboi M,Mano H,Doi T,Shitara K,Nishikawa H
- Journal Title
  
  Nature Immunology
  
  Volume: 21 Issue: 11 Pages: 1346-1358
- DOI
  10.1038/s41590-020-0769-3
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-20K08531, KAKENHI-PROJECT-20H03694, KAKENHI-PROJECT-18J21551, KAKENHI-PROJECT-18K07320, KAKENHI-PROJECT-19K22574, KAKENHI-PROJECT-17K15738, KAKENHI-PROJECT-17H06162, KAKENHI-PROJECT-16H06299
[Journal Article] Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors2019
- Author(s)
  Doi T, Yang JC, Shitara K, Naito Y, Cheng AL, Sarashina A, Pronk LC, Takeuchi Y, Lin CC
- Journal Title
  
  Targeted Oncol
  
  Volume: 14 Issue: 1 Pages: 57-65
- DOI
  10.1007/s11523-019-00620-0
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-17H06162
[Journal Article] A phase I study of ontuxizumab, a humanized monoclonal antibody targeting endosialin, in Japanese patients with solid tumors2019
- Author(s)
  Doi T, Aramaki T, Yasui H, Muro K, Ikeda M, Okusaka T, Inaba Y, Nakai K, Ikezawa H, Nakajima R
- Journal Title
  
  Invest New Drugs
  
  Volume: 37 Issue: 5 Pages: 1061-1074
- DOI
  10.1007/s10637-018-0713-7
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-17H06162
[Journal Article] Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor2019
- Author(s)
  Harding JJ, Bauer TM, Tan DSW, Bedard PL, Rodon J, Doi T, Schnell C, Iyer V, Baffert F, Radhakrishnan R, Fabre C, Juric D
- Journal Title
  
  Invest New Drugs
  
  Volume: 37 Issue: 2 Pages: 271-281
- DOI
  10.1007/s10637-018-0627-4
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-17H06162
[Journal Article] KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer2019
- Author(s)
  Kato K, Shah MA, Enzinger P, Bennouna J, Shen L, Adenis A, Sun JM, Cho BC, Ozguroglu M, Kojima T, Kostorov V, Hierro C, Zhu Y, McLean LA, Shah S, Doi T
- Journal Title
  
  Future Oncol
  
  Volume: 15 Issue: 10 Pages: 1057-1066
- DOI
  10.2217/fon-2018-0609
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-17H06162
[Journal Article] Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study2019
- Author(s)
  Tamura K, Tsurutani J, Takahashi S, Iwata H, Krop IE, Redfern C, Sagara Y, Doi T, Park H, Murthy RK, Redman RA, Jikoh T, Lee C, Sugihara M, Shahidi J, Yver A, Modi S
- Journal Title
  
  Lancet Oncol
  
  Volume: 20 Issue: 6 Pages: 816-826
- DOI
  10.1016/s1470-2045(19)30097-x
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-17H06162
[Journal Article] Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer2019
- Author(s)
  Mehnert JM, Varga A, Brose MS, Aggarwal RR, Lin CC, Prawira A, de Braud F, Tamura K, Doi T, Piha-Paul SA, Gilbert J, Saraf S, Thanigaimani P, Cheng JD, Keam B
- Journal Title
  
  BMC Cancer
  
  Volume: 19 Issue: 1 Pages: 196-196
- DOI
  10.1186/s12885-019-5380-3
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-17H06162
[Journal Article] Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer2019
- Author(s)
  Mishima S, Kawazoe A, Nakamura Y, Sasaki A, Kotani D, Kuboki Y, Bando H, Kojima T, Doi T, Ohtsu A, Yoshino T, Kuwata T, Tsuji A, Shitara K
- Journal Title
  
  J Immunother Cancer
  
  Volume: 7 Issue: 1 Pages: 24-24
- DOI
  10.1186/s40425-019-0514-3
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-17H06162
[Journal Article] Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study2019
- Author(s)
  Bang YJ, Kang YK, Catenacci DV, Muro K, Fuchs CS, Geva R, Hara H, Golan T, Garrido M, Jalal SI, Borg C, Doi T, Yoon HH, Savage MJ, Wang J, Dalal RP, Shah S, Wainberg ZA, Chung HC
- Journal Title
  
  Gastric Cancer
  
  Volume: 22 Issue: 4 Pages: 828-837
- DOI
  10.1007/s10120-018-00909-5
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-17H06162
[Journal Article] First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors2019
- Author(s)
  Shimomura A, Yamamoto N, Kondo S, Fujiwara Y, Suzuki S, Yanagitani N, Horiike A, Kitazono S, Ohyanagi F, Doi T, Kuboki Y, Kawazoe A, Shitara K, Ohno I, Banerji U, Sundar R, Ohkubo S, Calleja EM, Nishio M
- Journal Title
  
  Mol Cancer Ther
  
  Volume: 18 Issue: 3 Pages: 531-540
- DOI
  10.1158/1535-7163.mct-18-0831
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-17H06162
[Journal Article] Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial2019
- Author(s)
  Doi T, Iwasa S, Muro K, Satoh T, Hironaka S, Esaki T, Nishina T, Hara H, Machida N, Komatsu Y, Shimada Y, Otsu S, Shimizu S, Watanabe M
- Journal Title
  
  Gastric Cancer
  
  Volume: 22 Issue: 4 Pages: 817-827
- DOI
  10.1007/s10120-018-0903-1
- NAID
  40021926036
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-17H06162
[Journal Article] T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-0282019
- Author(s)
  Ott PA, Bang YJ, Piha-Paul SA, Razak ARA, Bennouna J, Soria JC, Rugo HS, Cohen RB, O'Neil BH, Mehnert JM, Lopez J, Doi T, van Brummelen EMJ, Cristescu R, Yang P, Emancipator K, Stein K, Ayers M, Joe AK, Lunceford JK
- Journal Title
  
  J Clin Oncol
  
  Volume: 37 Issue: 4 Pages: 318-327
- DOI
  10.1200/jco.2018.78.2276
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-17H06162
[Journal Article] Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study2019
- Author(s)
  Shitara K, Iwata H, Takahashi S, Tamura K, Park H, Modi S, Tsurutani J, Kadowaki S, Yamaguchi K, Iwasa S, Saito K, Fujisaki Y, Sugihara M, Shahidi J, Doi T
- Journal Title
  
  Lancet Oncol
  
  Volume: 20 Issue: 6 Pages: 827-836
- DOI
  10.1016/s1470-2045(19)30088-9
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-17H06162
[Journal Article] Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer.2019
- Author(s)
  Sasaki A, Nakamura Y, Mishima S, Kawazoe A, Kuboki Y, Bando H, Kojima T, Doi T, Ohtsu A, Yoshino T, Kuwata T, Akimoto T, Shitara K.
- Journal Title
  
  Gastric Cancer.
  
  Volume: 22 Issue: 4 Pages: 793-802
- DOI
  10.1007/s10120-018-00922-8
- NAID
  40021925994
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-19K08190, KAKENHI-PROJECT-16K10412, KAKENHI-PROJECT-17H06162
[Journal Article] First-in-human phase 1 study of novel dUTPase inhibitor TAS-114 in combination with S-1 in Japanese patients with advanced solid tumors2019
- Author(s)
  Doi T, Yoh K, Shitara K, Takahashi H, Ueno M, Kobayashi S, Morimoto M, Okusaka T, Ueno H, Morizane C, Okano N, Nagashima F, Furuse J
- Journal Title
  
  Invest New Drugs
  
  Volume: 37 Issue: 3 Pages: 507-518
- DOI
  10.1007/s10637-018-0697-3
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-17H06162
[Journal Article] Phase I study of ipatasertib as a single agent and in combination with abiraterone plus prednisolone in Japanese patients with advanced solid tumors2019
- Author(s)
  Doi T, Fujiwara Y, Matsubara N, Tomomatsu J, Iwasa S, Tanaka A, Endo-Tsukude C, Nakagawa S, Takahashi S
- Journal Title
  
  Cancer Chemother Pharmacol
  
  Volume: 84 Issue: 2 Pages: 393-404
- DOI
  10.1007/s00280-019-03882-7
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-17H06162
[Journal Article] A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors2019
- Author(s)
  Doi T, Muro K, Ishii H, Kato T, Tsushima T, Takenoyama M, Oizumi S, Gemmoto K, Suna H, Enokitani K, Kawakami T, Nishikawa H, Yamamoto N
- Journal Title
  
  Clin Cancer Res
  
  Volume: 25 Issue: 22 Pages: 6614-6622
- DOI
  10.1158/1078-0432.ccr-19-1090
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-17H06162
[Journal Article] Phase I dose-escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumors2019
- Author(s)
  Esaki T, Hirai F, Makiyama A, Seto T, Bando H, Naito Y, Yoh K, Ishihara K, Kakizume T, Natsume K, Myers A, Doi T
- Journal Title
  
  Cancer Sci
  
  Volume: 110 Issue: 4 Pages: 1340-1351
- DOI
  10.1111/cas.13956
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-17H06162
[Journal Article] A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1-4, as a single dose and multiple doses in patients with solid malignancies2019
- Author(s)
  Yamamoto N, Ryoo BY, Keam B, Kudo M, Lin CC, Kunieda F, Ball HA, Moran D, Komatsu K, Takeda K, Fukuda M, Furuse J, Morita S, Doi T
- Journal Title
  
  Invest New Drugs
  
  Volume: 38 Issue: 2 Pages: 445-456
- DOI
  10.1007/s10637-019-00780-w
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-17H06162
[Journal Article] Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein?Barr virus status, and cancer genome alterations in metastatic gastric cancer2018
- Author(s)
  Kawazoe Akihito、Shitara Kohei、Kuboki Yasutoshi、Bando Hideaki、Kojima Takashi、Yoshino Takayuki、Ohtsu Atsushi、Ochiai Atsushi、Togashi Yosuke、Nishikawa Hiroyoshi、Doi Toshihiko、Kuwata Takeshi
- Journal Title
  
  Gastric Cancer
  
  Volume: 22 Issue: 1 Pages: 69-76
- DOI
  10.1007/s10120-018-0843-9
- NAID
  40021775208
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-18K07007, KAKENHI-PROJECT-17K18388, KAKENHI-PROJECT-17H06162
[Journal Article] Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment2018
- Author(s)
  Tada Yasuko、Togashi Yosuke、Kotani Daisuke、Kuwata Takeshi、Sato Eichi、Kawazoe Akihito、Doi Toshihiko、Wada Hisashi、Nishikawa Hiroyoshi、Shitara Kohei
- Journal Title
  
  Journal for ImmunoTherapy of Cancer
  
  Volume: 6 Issue: 1 Pages: 106-106
- DOI
  10.1186/s40425-018-0403-1
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-17K18388, KAKENHI-PROJECT-17H06162
[Presentation] Dissecting Transcriptomic Heterogeneity In Primary Esophageal Squamous Cell Carcinoma By Single-Cell RNA Sequencing2021
- Author(s)
  Minamide T, Kashima Y, Irie T, Koyama S, Togashi Y, Suzuki, A, Yamashita H, Nakamura Y, Shitara K, Tanaka H, Yoshida T, Inaki K, Chihara M, Wada T, Nishimura K, Nakamura A, Murai S, Ohashi A, Suzuki Y, Tsuchihara K, Nishikawa H, Yano T, Doi T
- Organizer
  Digestive Disease Week (DDW) 2021
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-17H06162
[Presentation] Association of gut microbiome with immune status and clinical response in solid tumor patientswho received on anti-PD-12018
- Author(s)
  Shota Fuoka,Motooka Daisuke, Yosuke Togashi,Eri Sugiyama,Hibiki Udagawa,Keisuke Kirita,Takahiro Kamada,Akihito Kawazoe,Koichi Goto,Toshihiko Doi,Kohei Shitara,Shota Nakamura,Hiroyoshi Nishikawa
- Organizer
  2018 ASCO ANNUAL MEETING
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-17H06162
[Presentation] An open label phase I study to evaluate the safety and efficacy of OBP-301 with permbrolizumab in patients with advanced solid tumors2018
- Author(s)
  TakashiKojima,Toshiyoshi Fujiwara,Yasuhiro Shirakawa,Hiromi Ono,Masako Nakamoto,Hiromi Hasegawa,Nami Hirano, Masashi Wakabayashi,Shogo Nomura,Yosuke Togashi,Hiroyoshi Nishikawa,Akihiro Sato,Atsushi Ohtsu,Toshihiko Doi
- Organizer
  2018 ASCO ANNUAL MEETING
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-17H06162

1. Nishikawa Hiroyoshi (10444431)

# of Collaborated Projects: 3 results

# of Collaborated Products: 5 results
2. Sugiyama Daisuke (90759375)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
3. Kogawa Takahiro (70444916)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
4. 設楽紘平 (20730419)

# of Collaborated Projects: 1 results

# of Collaborated Products: 1 results
5. 藤井誠志 (30314743)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
6. 原野謙一 (80627258)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
7. 内藤陽一 (90590373)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
8. 河野隆志 (80280783)

# of Collaborated Projects: 1 results

# of Collaborated Products: 2 results
9. NISHINAKAMURA Hitomi

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
10. 桑田健

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
11. 板橋耕太

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
12. 冨樫庸介

# of Collaborated Projects: 0 results

# of Collaborated Products: 2 results
13. 秋元哲夫

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
14. 島村徹平

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results

doi toshihiko 土井 俊彦

Doi Toshihiko 土井 俊彦

Research Projects

Research Products

Co-Researchers

New Classification of triple negative breast cancer (TNBC) based on immune status with clinical characteristic

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Immunosuppressive mechanisms for anti-tumor immune responses depending on antigenicity

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Association of immune responses with racial differences of cancer development

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Identification of new molecule for regulatory T cells in an anti-tumor immunity

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

[Journal Article] Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments2022

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Potentiality of multiple modalities for single-cell analyses to evaluate the tumor microenvironment in clinical specimens2021

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Depletion of central memory CD8+ T cells might impede the antitumor therapeutic effect of Mogamulizumab2021

Author(s)

Journal Title

DOI

Data Source

[Journal Article] The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies2020

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors2019

Author(s)

Journal Title

DOI

Data Source

[Journal Article] A phase I study of ontuxizumab, a humanized monoclonal antibody targeting endosialin, in Japanese patients with solid tumors2019

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor2019

Author(s)

Journal Title

DOI

Data Source

[Journal Article] KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer2019

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study2019

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer2019

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer2019

doi toshihiko 土井俊彦

Doi Toshihiko 土井俊彦